Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS clinical trials group study

Journal of Infectious Diseases

Volumn 194, Issue 8, 2006, Pages 1098-1107

  Haas, David W ^a,g   Geraghty, Daniel E ^b   Andersen, Janet ^c,d   Mar, Jessica ^c,d   Motsinger, Alison A ^a   D'Aquila, Richard T ^a   Unutmaz, Derya ^a   Benson, Constance A ^e   Ritchie, Marylyn D ^a   Landay, Alan ^f  

^a VANDERBILT UNIVERSITY   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Children's Oncology Group Statistics and Data Center   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; BETA INTERFERON; BIM PROTEIN; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 7; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; APOPTOSIS; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENETICS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIREMIA;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOPTOSIS REGULATORY PROTEINS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; MALE; MEMBRANE GLYCOPROTEINS; POLYMORPHISM, GENETIC; PUERTO RICO; RECEPTORS, INTERLEUKIN-15; RECEPTORS, INTERLEUKIN-2; RETROSPECTIVE STUDIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 33749595954     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/507313     Document Type: Article

References (47)

1. McCune JM, Hanley MB, Cesar D, et al. Factors influencing T-cell turnover in HIV-1-seropositive patients. J Clin Invest 2000; 105:R1-8.
2. Stellbrink HJ, van Lunzen J. Lymph nodes during antiretroviral therapy. Curr Opin Infect Dis 2001; 14:17-22.
3. + T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis 2002; 185:315-23.
4. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (updated 6 October 2005). Available at: http://aidsinfo.nih.gov/guidelines/ GuidelineDetail.aspx?Menultem = Guidelines&Search =Off& GuidelineID = 7&ClassID = 1. Accessed 20 March 2006.
5. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341:1865-73.
6. Lederman MM, McKinnis R, Kelleher D, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS 2000; 14:2635-42.
7. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 178:70-9.
8. Keita-Perse O, Roger PM, Pradier C, Pugliese P, Cottalorda J, Dellamonica P. Do viral load and CD8 cell count at initiation of tritherapy influence the increase of CD4 T-cell count? AIDS 1998; 12:FI75-9.
9. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999; 13:669-76.
10. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003; 3:269-79.
11. Khaled AR, Durum SK. Lymphocide: cytokines and the control of lymphoid homeostasis. Nat Rev Immunol 2002; 2:817-30.
12. Lodolce JP, Boone DL, Chai S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9:669-76.
13. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000; 1:426-32.
14. Kanegane H, Tosato G. Activation of naive and memory T cells by interleukin-15. Blood 1996; 88:230-5.
15. Maraskovsky E, O'Reilly LA, Teepe M, Corcoran LM, Peschon JJ, Strasser A. Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1 -/- mice. Cell 1997; 89:1011-9.
16. Vella AT, Dow S, Potter TA, Kappler J, Marrack P. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95:3810-5.
17. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240:1169-76.
18. Leung DT, Morefield S, Willerford DM. Regulation of lymphoid homeostasis by 1L-2 receptor signals in vivo. J Immunol 2000; 164:3527-34.
19. Lin JX, Migone TS, Tsang M, et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 1995; 2:331-9.
20. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33:29-55.
21. Miura Y, Misawa N, Maeda N, et al. Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice. J Exp Med 2001; 193:651-60.
22. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995; 81:495-504.
23. Gupta S. Molecular steps of death receptor and mitochondrial pathways of apoptosis. Life Sci 2001; 69:2957-64.
24. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002; 9:459-70.
25. Strasser A, Harris AW, Huang DC, Krammer PH, Cory S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 1995; 14:6136-47.
26. Van PL, Biuckians A, Abbas AK. Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. J Immunol 1998; 160:2065-71.
27. Hildeman DA, Zhu Y, Mitchell TC, Kappler J, Marrack P. Molecular mechanisms of activated T cell death in vivo. Curr Opin Immunol 2002; 14:354-9.
28. Bouillet P, Metcalf D, Huang DC, ct al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286:1735-8.
29. Herbeuval JP, Hardy AW, Boasso A, et al. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type 1 IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2005; 102:13974-9.
30. Haas DW, Wilkinson GR, Kuritzkes DR, et al. A multi-investigator/ institutional DNA bank for AIDS-related human genetic studies: AACTG protocol A5128. HIV Clin Trials 2003; 4:287-300.
31. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000; 132:365-86.
32. Smit AF. Interspersed repeats and other mementos of transposable elements in mammalian genomes. Curr Opin Genet Dev 1999; 9:657-63.
33. Murphy WJ, Bourque G, Tesler G, Pevzner P, O'Brien SJ. Reconstructing the genomic architecture of mammalian ancestors using multispecies comparative maps. Hum Genomics 2003; 1:30-40.
34. Margulies EH, Green ED. Detecting highly conserved regions of the human genome by multispecies sequence comparisons. Cold Spring Harb Symp Quant Biol 2003; 68:255-63.
35. Geraghty DE, Fortelny S, Guthrie B, et al. Data acquisition, data storage, and data presentation in a modern genetics laboratory. Rev Immunogenet 2000; 2:532-40.
36. Geraghty DE, Daza R, Williams LM, Vu Q, Ishitani A. Genetics of the immune response: identifying immune variation within the MHC and throughout the genome. Immunol Rev 2002; 190:69-85.
37. Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 1998; 8:175-85.
38. Gordon D, Abajian C, Green P. Consed: a graphical tool for sequence finishing. Genome Res 1998; 8:195-202.
39. Smith WP, Vu Q, Li SS, Hansen JA, Zhao LP, Geraghty DE. Toward understanding MHC disease associations: partial resequencing of 46 distinct HLA haplotypes. Genomics 2006; 87:561-71.
40. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997; 25:2745-51.
41. Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69:138-47.
42. Ritchie MD, Hahn LW, Moore JH. Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 2003; 24:150-7.
43. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003; 19:376-82.
44. + lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999; 103:1391-8.
45. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29:306-9.
46. Colhoun HM, McKeigue PM, Davey SG. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361:865-72.
47. Freimer NB, Sabatti C. Guidelines for association studies in human molecular genetics. Hum Mol Genet 2005; 14:2481-3.